Background: COVID-19 has several overlapping phases. Treatments to date have focused on
the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase …

The rational combination of recombinant IFN-α2b and IFN-γ resulted in a new formulation of
interferons (HeberFERON) with improved pharmacodynamics. In basal cell carcinomas …

Background Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea
form lesions) are therapeutically challenging because they require considerable tissue …

Background High antibiotic resistance is described in atypical Mycobacteriosis, mainly by
Mycobacterium avium complex (MAC). Methods A randomized, double-blind, placebo-…

Purpose: This work is aimed to show briefly, the clinical development of a new pharmaceutical
formulation of interferons for the treatment of basal cell carcinoma. Methods: A rationale …

Background More potent antitumor activity is desired in Interferon (IFN)-treated cancer
patients. This could be achieved by combining IFN alpha and IFN gamma. The aim of this work …

Background Interferon (IFN) alpha conjugation to polyethylene glycol (PEG) results in a
better pharmacokinetic profile and efficacy. The aim of this study was to compare the …

In contrast to two‐chain urokinase (uPA), a chemical conjugate between uPA and native
saporin (a cytotoxic plant seed ribosome‐inactivating protein) did not require plasminogen …

INTRODUCTION Interferons have been used to treat basal cell carcinoma with positive
results. Cuba’s Genetic Engineering and Biotechnology Center developed HeberPAG, a …

Background The synergistic combination of interferon (IFN) alpha-2b and IFN gamma results
in more potent in vitro biological effects mediated by both IFNs. The aim of this investigation …